Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Sep;30(9):1873-1881.
doi: 10.1007/s10147-025-02817-y. Epub 2025 Jun 30.

Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis

Laura Vertechy  1 , Raffaella Ergasti #  1 , Cristina Chiamenti  2 , Davide Arrigo  3 , Ilary Ruscito  1 , Alessandra Rizzi  3 , Serena Maria Boccia  1 , Carolina Maria Sassu  1 , Giovanni Scambia  1   3 , Anna Fagotti  4   5 , Claudia Marchetti  1   3
Affiliations
Observational Study

Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis

Laura Vertechy et al. Int J Clin Oncol. 2025 Sep.

Abstract

Background: Prognosis for patients with early platinum-resistant Epithelial Ovarian Cancer (EOC) relapse after first-line chemotherapy remains poor. This study explores whether platinum rechallenge may be an option in this setting.

Methods: In this retrospective, single-institute, observational study, we enrolled BRCA1/2 wild-type (BRCAwt) patients who underwent surgery (January 2017-July 2021) and relapsed within 6 months after first-line platinum-based chemotherapy. Platinum (P) rechallenge was compared with pegylated liposomal doxorubicin (PLD) or non-platinum/non-PLD therapy (weekly paclitaxel/gemcitabine/topotecan, PGT). To minimize selection bias, propensity score matching (PSM) analysis was performed.

Results: Overall, 87 patients were identified: 18 (20.7%, P cohort), 50 (57.5%, PLD cohort) and 19 (21.8%, PGT cohort); after PSM, 54/87 patients were identified with similar characteristics, 18 for each group. Grade 3/4 toxicity events were more frequent in P group patients (13/18, 72.2%), compared to PDL (5/18, 27.8%) and PGT (7/18, 38.9%)(PvsPDL: p = 0.008; PvsPGT: p = 0.044; PDLvsPGT: p = 0.479; PvsPDLvsPGT: p = 0.021). Median progression-free survival (mPFS) was 9 months (P cohort) (CI 95%; 4.842-13.158), achieving a 4-month and 3-month increase compared to PLD (mPFS 5 months, p < 0.002) and PGT group (mPFS 6 months, p < 0.05), respectively. Median overall survival (mOS) benefit was preserved: 32 months (P cohort) compared to PLD (13 months, p = 0.001) and PGT (18 months, p = 0.01) groups. On multivariate analysis, platinum rechallenge was an independent prognostic factor for PFS (HR: 0.416; 95% CI: 0.215-0.807; p = 0.009) and OS (HR: 0.175; 95% CI: 0.061-0.503; p = 0.001). Results were consistent with the whole population.

Conclusions: Platinum rechallenge showed promising survival outcomes for BRCAwt patients recurring within 6 months after first-line platinum-based chemotherapy.

Keywords: Ovarian cancer; Platinum resistant; Platinum-rechallenge; Propensity score matching; Survival.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors have no competing interests to declare that are relevant to the content of this article.

References

    1. Lheureux S, Gourley C, Vergote I et al (2019) Epithelial ovarian cancer. The Lancet 393:1240–1253. https://doi.org/10.1016/S0140-6736(18)32552-2 - DOI
    1. Vergote I, Denys H, De Greve J et al (2020) Treatment algorithm in patients with ovarian cancer. Facts Views Vis ObGyn 12:227–239 (PMID: 33123697 PMCID: PMC7580261) - PubMed - PMC
    1. Davis A, Tinker AV, Friedlander M (2014) “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 133:624–631. https://doi.org/10.1016/j.ygyno.2014.02.038 - DOI - PubMed
    1. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026 - DOI - PubMed
    1. Nasu H, Nishio S, Park J et al (2022) Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer. Int J Clin Oncol 27:790–801. https://doi.org/10.1007/s10147-021-02103-7 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources